Skip to main content
Year archive

H. Lundbeck A — 2018 filings

All 63 regulatory filings released by H. Lundbeck A (HLUN) in 2018, sourced directly from the official regulator.

63 Filings
2018 Period
2018 filings (63)
Filing Released Lang
Lundbeck announces retirement of Anders Gersel Pedersen, EVP and Head of Research and Development
Regulatory Filings
2018-12-04 English
Board/Management Information 2018
Board/Management Information
2018-12-04 English
Board/Management Information 2018
Board/Management Information
2018-12-04 Danish
Board/Management Information 2018
Board/Management Information
2018-12-04 English
Anders Gersel Pedersen, koncerndirektør for forskning og udvikling hos Lundbeck, går på pension
Board/Management Information
2018-12-04 English
Anders Gersel Pedersen, koncerndirektør for forskning og udvikling hos Lundbeck, går på pension
Board/Management Information
2018-12-04 English
Ledende medarbejderes og deres nærtståendes transaktioner med aktier og tilknyttede værdipapirer i H. Lundbeck A/S
Director's Dealing
2018-12-03 English
Director's Dealing 2018
Director's Dealing
2018-12-03 English
Earnings Release 2018
Earnings Release Q4 2018
2018-11-30 Danish
Legal Proceedings Report 2018
Legal Proceedings Report
2018-11-30 English
Lundbeck og Otsuka rapporterer positive fase II-data for kombinationsbehandling med brexpiprazol og sertralin til behandling af post-traumatisk stress syndrom (PTSD)
Regulatory Filings
2018-11-30 English
Lundbeck og Otsuka rapporterer positive fase II-data for kombinationsbehandling med brexpiprazol og sertralin til behandling af post-traumatisk stress syndrom (PTSD)
Regulatory Filings
2018-11-30 Danish
Kapitalforhøjelse i Lundbeck med 6.574 aktier (0,0033 % af udestående aktier) som følge af warrant-program for medarbejdere
Share Issue/Capital Change
2018-11-20 English
Kapitalforhøjelse i Lundbeck med 6.574 aktier (0,0033 % af udestående aktier) som følge af warrant-program for medarbejdere
Share Issue/Capital Change
2018-11-20 English
Kapitalforhøjelse i Lundbeck med 6.574 aktier (0,0033 % af udestående aktier) som følge af warrant-program for medarbejdere
Share Issue/Capital Change
2018-11-20 Danish
Kapitalforhøjelse i Lundbeck med 6.574 aktier (0,0033 % af udestående aktier) som følge af warrant-program for medarbejdere
Share Issue/Capital Change
2018-11-20 Danish
Earnings Release 2018
Earnings Release 9M 2018
2018-11-07 English
Lundbeck realized 12% growth in revenue (local currencies) and 56% growth in EPS in 9M 2018. Guidance for FY2018 raised
Interim / Quarterly Report 9M 2018
2018-11-07 English
Regulatory Filings 2018
Regulatory Filings
2018-10-25 English
Regulatory Filings 2018
Regulatory Filings
2018-10-25 Danish
Lundbeck opdaterer om klinisk fase III studie af Lu AF35700 til behandlingsresistent skizofreni
Regulatory Filings
2018-10-25 English
Lundbeck opdaterer om klinisk fase III studie af Lu AF35700 til behandlingsresistent skizofreni
Regulatory Filings
2018-10-25 Danish
Earnings Release 2018
Earnings Release H1 2018
2018-08-08 English
Lundbeck realized 14% growth in revenue (local currencies) and 83% growth in EPS
Interim / Quarterly Report H1 2018
2018-08-08 English
Board/Management Information 2018
Board/Management Information
2018-07-02 English
Board/Management Information 2018
Board/Management Information
2018-07-02 English
Dr. Deborah Dunsire named new President and CEO of Lundbeck
Board/Management Information
2018-07-02 English
Dr. Deborah Dunsire named new President and CEO of Lundbeck
Board/Management Information
2018-07-02 Danish
Regulatory Filings 2018
Regulatory Filings
2018-06-08 English
Legal Proceedings Report 2018
Legal Proceedings Report
2018-06-08 Danish
Positive clinical phase III results of vortioxetine in Japanese adults with Major Depressive Disorder
Regulatory Filings
2018-06-08 Danish
Positive clinical phase III results of vortioxetine in Japanese adults with Major Depressive Disorder
Regulatory Filings
2018-06-08 English
Legal Proceedings Report 2018
Legal Proceedings Report
2018-06-06 English
Legal Proceedings Report 2018
Legal Proceedings Report
2018-06-06 English
Lundbeck reaches voluntary agreement in principle with U.S. Department of Justice
Legal Proceedings Report
2018-06-06 Danish
Lundbeck reaches voluntary agreement in principle with U.S. Department of Justice
Legal Proceedings Report
2018-06-06 English
Lundbeck increases its share capital by 41,946 shares (0.0211 % of outstanding shares) as a result of exercise of employee warrants
Share Issue/Capital Change
2018-05-23 Danish
Lundbeck increases its share capital by 41,946 shares (0.0211 % of outstanding shares) as a result of exercise of employee warrants
Share Issue/Capital Change
2018-05-23 Danish
Lundbeck increases its share capital by 41,946 shares (0.0211 % of outstanding shares) as a result of exercise of employee warrants
Share Issue/Capital Change
2018-05-23 English
Lundbeck increases its share capital by 41,946 shares (0.0211 % of outstanding shares) as a result of exercise of employee warrants
Share Issue/Capital Change
2018-05-23 English
Regulatory Filings 2018
Regulatory Filings
2018-05-03 Danish
Regulatory Filings 2018
Regulatory Filings
2018-05-03 English
Regulatory Filings 2018
Regulatory Filings
2018-05-03 English
Regulatory Filings 2018
Regulatory Filings
2018-05-03 English
FDA opdaterer indlægssedlen for Trintellix® (vortioxetin) til at inkludere data vedrørende forbedring i proceshastighed, et vigtigt aspekt i kognitiv funktionsevne ved akut depression (MDD)
Regulatory Filings
2018-05-02 Danish
FDA opdaterer indlægssedlen for Trintellix® (vortioxetin) til at inkludere data vedrørende forbedring i proceshastighed, et vigtigt aspekt i kognitiv funktionsevne ved akut depression (MDD)
Regulatory Filings
2018-05-02 Danish
FDA opdaterer indlægssedlen for Trintellix® (vortioxetin) til at inkludere data vedrørende forbedring i proceshastighed, et vigtigt aspekt i kognitiv funktionsevne ved akut depression (MDD)
Regulatory Filings
2018-05-02 English
Legal Proceedings Report 2018
Legal Proceedings Report
2018-04-27 English
Legal Proceedings Report 2018
Legal Proceedings Report
2018-04-27 English
The Drug Committee of Ministry of Health, Labour and Welfare in Japan has accepted a 2-year extension of market exclusivity of Lexapro®
Regulatory Filings
2018-04-27 Danish
The Drug Committee of Ministry of Health, Labour and Welfare in Japan has accepted a 2-year extension of market exclusivity of Lexapro®
Regulatory Filings
2018-04-27 Danish
M&A Activity 2018
M&A Activity
2018-03-16 Danish
M&A Activity 2018
M&A Activity
2018-03-16 English
Lundbeck opkøber Prexton Therapeutics og tilføjer derved foliglurax, som er i klinisk fase II, til sin portefølje af innovative behandlinger til patienter, der lider af Parkinsons sygdom
M&A Activity
2018-03-16 English
Lundbeck opkøber Prexton Therapeutics og tilføjer derved foliglurax, som er i klinisk fase II, til sin portefølje af innovative behandlinger til patienter, der lider af Parkinsons sygdom
M&A Activity
2018-03-16 English
Kapitalforhøjelse i Lundbeck med 8.668 aktier (0,0044 % af udestående aktier) som følge af warrant-program for medarbejdere
Share Issue/Capital Change
2018-02-20 English
Kapitalforhøjelse i Lundbeck med 8.668 aktier (0,0044 % af udestående aktier) som følge af warrant-program for medarbejdere
Regulatory Filings
2018-02-20 English
Kapitalforhøjelse i Lundbeck med 8.668 aktier (0,0044 % af udestående aktier) som følge af warrant-program for medarbejdere
Share Issue/Capital Change
2018-02-20 English
Kapitalforhøjelse i Lundbeck med 8.668 aktier (0,0044 % af udestående aktier) som følge af warrant-program for medarbejdere
Regulatory Filings
2018-02-20 Danish
Annual Report 2017
Annual Report FY 2017
2018-02-07 English
Annual Report 2017 for H. Lundbeck A/S
Regulatory Filings
2018-02-07 English
Earnings Release 2017
Earnings Release FY 2017
2018-02-07 English
Lundbeck delivers its best financial results following 10% revenue growth and 117% growth in net profit
Annual Report FY 2017
2018-02-07 English